Neurotrope and Metuchen merge to form Petros

18 May 2020

US firms Neurotrope (Nasdaq: NTRP) and Metuchen Pharmaceuticals are to merge in an all-stock transaction resulting in a newly-formed holding company to be renamed Petros Pharmaceuticals.

This merger is expected to create a Nasdaq-traded company focused solely on men's health conditions. Its cornerstone product will be the erectile dysfunction treatment Stendra (avanafil), looking to build on $25 million of 2019 gross sales.

"Petros provides a platform to create the first publicly-traded biopharmaceutical company focused exclusively on US Food and Drug Administration (FDA)-approved treatments for men's health conditions"Petros’ pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, along with a business development program exploring various men's health products, including endothelial dysfunction, prostate cancer, psychosexual and psychosocial ailments, hormone health and substance use disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK